Related references
Note: Only part of the references are listed.Supervised molecular dynamics for exploring the druggability of the SARS-CoV-2 spike protein
Giuseppe Deganutti et al.
JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN (2021)
Remdesivir for the Treatment of Covid-19-Final Report
John H. Beigel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Evolutionary origins of the SARS-CoV-2 sarbecovirus lineage responsible for the COVID-19 pandemic
Maciej F. Boni et al.
NATURE MICROBIOLOGY (2020)
Approaching coronavirus disease 2019: Mechanisms of action of repurposed drugs with potential activity against SARS-CoV-2
Lucia Lisi et al.
BIOCHEMICAL PHARMACOLOGY (2020)
Basic & Clinical Pharmacology & Toxicology Policy for Experimental and Clinical studies
Pernille Tveden-Nyborg et al.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2018)
Coronavirus S protein-induced fusion is blocked prior to hemifusion by Abl kinase inhibitors
Jeanne M. Sisk et al.
JOURNAL OF GENERAL VIROLOGY (2018)
Abelson Kinase Inhibitors Are Potent Inhibitors of Severe Acute Respiratory Syndrome Coronavirus and Middle East Respiratory Syndrome Coronavirus Fusion
Christopher M. Coleman et al.
JOURNAL OF VIROLOGY (2016)
Repurposing of Clinically Developed Drugs for Treatment of Middle East Respiratory Syndrome Coronavirus Infection
Julie Dyall et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL
Hagop Kantarjian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Share Paper
